57-83-0|Progesterone|Progesterone, Endogenous progesterone receptor agonist|MFCD00003658-范德生物科技公司

Progesterone

NMR下载 COA and HPLC MSDS下载
names：
Progesterone, Endogenous progesterone receptor agonist
CAS号：
57-83-0
MDL Number： MFCD00003658
MF(分子式)： C21H30O2 MW(分子量)： 314.47
EINECS:200-350-6 Reaxys Number:No data available
Pubchem ID:5994 Brand:BIOFOUNT

黄体酮(57-83-0,Progesterone,P4,Pregn-4-ene-3,20-dione)又称为孕酮，黄体酮是一种类固醇激素，黄体酮可调节月经周期，黄体酮对怀孕很重要。

货品编码	规格	纯度	价格 (¥)	现价(¥)	库存描述	数量	总计 (¥)
JZ0047-100g	100g	98%	¥ 1168.00	¥ 1168.00	Instock,1days	- +	¥ 0.00
JZ0047-25g	25g	98%	¥ 346.00	¥ 346.00	Instock,1days	- +	¥ 0.00
JZ0047-5g	5g	98%	¥ 156.00	¥ 156.00	Instock,1days	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Progesterone(57-83-0);黄体酮;孕酮;助孕素;孕烯二酮;孕激素; 鲁特伦;叶黄素; 黄酮 Corporin; 黄体激素;内源性孕激素受体激动剂
英文别名	Progesterone(57-83-0),Progesterone solution,Pregnenedione;Progesterone, (13 alpha,17 alpha)-(+-)-Isomer;Progesterone, (17 alpha)-Isomer Progesterone, (9 beta,10 alpha)-Isomer;
CAS号	57-83-0
SMILES	CC（= O）C1CCC2C1（CCC3C2CCC4 = CC（= O）CCC34C）C
Inchi	InChI = 1S / C21H30O2 / c1-13（22）17-6-7-18-16-5-4-14-12-15（23）8-10-20（14,2）19（16）9- 11-21（17,18）3 / h12,16-19H，4-11H2,1-3H3 / t16-，17 +，18-，19-，20-，21 + / m0 / s1
InchiKey	RJKFOVLPORLFTN-LEKSSAKUSA-N
分子式 Formula	C21H30O2
分子量 Molecular Weight	314.47
闪点 FP	166.7°C
熔点 Melting point	250至252°F（NTP，1992）
沸点 Boiling point	394.13°C
Polarizability极化度	No data available
密度 Density	1.1±0.1克/立方厘米
蒸汽压 Vapor Pressure	在25°C（est）下为3.59X10-4 mm Hg
溶解度Solubility
性状	白色结晶性粉末或Yellow to yellow-brown powder
储藏条件 Storage conditions	储存在-20°C,正确存储后，从分析证明书中提供的质量检查日期起2年.

黄体酮(57-83-0,Progesterone,P4,Pregn-4-ene-3,20-dione)毒理性质：
In large prospective trials of levonorgestrel as emergency contraception that included laboratory testing, mean serum ALT and AST levels remained unchanged and only rare, minor elevations of serum enzymes occurred that were invariably transient, not accompanied by jaundice or symptoms and not considered related to the emergency contraception. Despite widescale use of levonorgestrel for several decades, there have been no published reports of hepatotoxicity attributable to its use as emergency contraception. Likelihood score: E (unlikely cause of clinically apparent liver injury).

黄体酮(57-83-0,Progesterone,P4,Pregn-4-ene-3,20-dione)实验注意事项：
1.使用57-83-0实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.使用57-83-0实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品57-83-0的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品57-83-0时尽量采用多个药勺分别使用，使用后清洗干净。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
大规格定制：定制产品请将信息发送至sales@bio-fount.com。
黄体酮(57-83-0,Progesterone,P4,Pregn-4-ene-3,20-dione)Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags:黄体酮试剂,黄体酮杂质,黄体酮中间体,黄体酮密度,黄体酮溶解度,黄体酮旋光度,黄体酮结构式,黄体酮购买,黄体酮MSDS,黄体酮闪点,

产品说明	黄体酮(57-83-0)是内源性孕激素受体(PR)激动剂,黄体酮是一种天然类固醇和孕激素,黄体酮溶解度,黄体酮MSDS,黄体酮结构式详见主页.
Introduction	黄体酮(57-83-0,Progesterone,P4,Pregn-4-ene-3,20-dione) is an endogenous progesterone receptor (PR) agonist, progesterone is a natural steroid and progesterone,
Application1	孕酮（P4）是一种天然类固醇和孕激素，与人类和其他物种的月经周期，妊娠和胚胎发生有关.
Application2
Application3

黄体酮(57-83-0,Progesterone,P4,Pregn-4-ene-3,20-dione)药理学：

1、黄体酮又称为孕酮，也称为乙二醇或可丽酮，属于有机化合物，P4称为葡萄糖/盐皮质激素，孕激素及其衍生物。这些是具有基于羟基化的前列腺素部分的结构的类固醇。因此，黄体酮被认为是类固醇脂质分子。黄体酮是一种用于补充或替代孕酮的药物，是孕激素缺乏症不育妇女辅助生殖技术（艺术）治疗和继发性闭经的治疗方法。还用于减少接受雌激素替代疗法的绝经后妇女子宫内膜增生的发生率和伴随的子宫内膜癌风险，以及在缺乏器质性病变（如肌瘤或子宫癌）的情况下治疗由于荷尔蒙失调引起的异常子宫出血。黄体酮以固体形式存在，被认为实际上是不溶的（在水），并且相对中性。在大多数人体组织中都发现了黄体酮，并且在多种生物流体（例如血液，脑脊液和尿液）中也检测到了黄体酮。在细胞内，黄体酮主要位于细胞质，膜（由logP预测）和内质网中。黄体酮参与许多酶促反应。尤其是，黄体酮可以转化为脱氧皮质酮。黄体酮是由类固醇21-羟化酶介导的。此外，黄体酮可以由孕烯醇酮合成通过其与3-β-HSD酶1的相互作用。在人类中，黄体酮参与类固醇生成途径。黄体酮还参与几种代谢性疾病，其中一些疾病包括5型肾上腺增生或由于17α-羟化酶缺乏症引起的先天性肾上腺增生，先天性类脂肾上腺增生（clah）或类脂cah途径，17-α-羟化酶缺乏症（cyp17 ）和11-β-羟化酶缺乏症（cyp11b1）。在人体之外，许多食品中都含有黄体酮，例如山萝卜，新西兰的菠菜和花生。这使得黄体酮成为食用这些食品的潜在生物标记。

2、黄体酮又称为孕激素治疗剂，黄体酮是天然激素孕激素的治疗形式。黄体酮与孕酮受体结合，导致热休克蛋白解离，受体磷酸化以及通过与转录因子直接或间接相互作用而引起的转录激活。该药物通过减少雌激素受体的数量并增加其代谢成无活性代谢物的作用，对雌激素产生抑制作用。黄体酮在子宫内膜中引起分泌变化，在怀孕期间降低子宫收缩力，并维持妊娠。

3、黄体酮是一种C21类固醇激素，黄体酮其中孕烷骨架在3和20位带有氧代取代基，在C（4）-C（5）不饱和。作为激素，黄体酮参与女性和其他物种的女性月经周期，怀孕和胚胎发生。黄体酮具有避孕药，孕激素，黄体酮是孕激素受体激动剂，黄体酮是人类代谢产物和小鼠代谢产物的作用。黄体酮是20-氧代类固醇，3-氧代-Delta（4）类固醇和C21-类固醇激素。黄体酮从一个导出氢化一个的孕烷。

4、黄体酮是内源性孕激素受体(PR)激动剂(C-21类固醇激素),黄体酮参与女性和其他物种的女性月经周期，妊娠和胚胎发生。目标:黄体酮也称为P4(pregn-4-ene-3,20-dione)是一种C-21类固醇激素,是主要的天然人类孕激素。黄体酮给药途径会影响药物的作用。口服给予黄体酮的人与人之间的吸收和生物利用度差异很大，而人工合成的黄体酮比黄体酮可被快速吸收半衰期更长并能保持血液中的稳定水平。孕酮不溶于水，口服时吸收不良，除非在油中微粉化。产品通常以含微粉化孕酮油的胶囊的形式出售。

警示图
危险性	Warning
危险性警示	LD50 intraperitoneal in rat: 327mg/kg，57-83-0(Hazardous Substances Data)，
安全声明	H351
安全防护	36/37-45-53-16
备注

黄体酮(57-83-0,Progesterone,P4,Pregn-4-ene-3,20-dione)危害标识：

象形图
信号	Danger
GHS危险说明	Aggregated GHS information provided by 241 companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
	H350 (13.69%): May cause cancer [Danger Carcinogenicity]
	H351 (85.06%): Suspected of causing cancer [Warning Carcinogenicity]
	H360 (80.08%): May damage fertility or the unborn child [Danger Reproductive toxicity]
	H361 (18.26%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
	H362 (24.48%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]
	Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
防范说明代码	P201, P202, P260, P263, P264, P270, P281, P308+P313, P405, and P501
防范说明代码	(The corresponding statement to each P-code can be found at the GHS Classification page.)

Schindler AE, et al. Classification and pharmacology of progestins. Maturitas. 2003 Dec 10;46 Suppl 1:S7-S16.

Zava DT, et al. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med. 1998 Mar;217(3):369-78.

Komesaroff PA, et al. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. 2001 Jun;4(2):144-50.

Girling JE, et al. Progesterone, but not estrogen, stimulates vessel maturation in the mouse endometrium. Endocrinology. 2007 Nov;148(11):5433-41. Epub 2007 Aug 9.

Vasquez, L.; Alarcon, J.; Zunza, H.; Becerra, J.; Silva, M. Chemical-microbiological synthesis of progesterone. Boletin de la Sociedad Chilena de Quimica (2001), 46(1), 29-31.

黄体酮(57-83-0,Progesterone,P4,Pregn-4-ene-3,20-dione)参考文献：

1.The progesterone level, leukocyte count and disgust sensitivity across the menstrual cycle.
?ela?niewicz A1, Borkowska B2, Nowak J3, Paw?owski B4. Physiol Behav. 2016 Apr 11. pii: S0031-9384(16)30136-6. doi: 10.1016/j.physbeh.2016.04.002. [Epub ahead of print]

According to the compensatory prophylaxis hypothesis, women in the luteal phase, characterized by a high progesterone level, which suppresses various mechanisms of immune response, should exhibit higher disgust sensitivity, compared to the follicular phase. In this study we test the hypothesis on the compensatory role of disgust sensitivity at the luteal phase of the menstrual cycle, when immune functions are expected to change due to a rise in progesterone level. Disgust sensitivity, progesterone level (P) and white blood cell count (WBC), a general marker of immunocompetence, were measured in 30 healthy women of reproductive age. Disgust sensitivity was evaluated with: 1) Disgust Scale Revised (DS-R) containing three subscales: Core Disgust, Animal Reminder and Contamination Disgust, 2) Pathogen Disgust and Moral Disgust domains of the Three-Domain Disgust Scale. Measurements were conducted twice - in menstruation (the lowest P) and in the mid-luteal phase (the highest P).

2.Night work and breast cancer risk defined by human epidermal growth factor receptor-2 (HER2) and hormone receptor status: A population-based case-control study in France.
Cordina-Duverger E1, Koudou Y1, Truong T1, Arveux P2, Kerbrat P3, Menegaux F1, Guénel P1. Chronobiol Int. 2016 Apr 14:1-5. [Epub ahead of print]

Night work has been associated with risk of breast cancer but this association needs to be confirmed. Because breast cancer is an etiologically heterogeneous disease, we explored the association of night work with breast cancer subtypes defined by tumor status (positive of negative) for estrogen-receptor (ER), progesterone-receptor (PR) and human epidermal growth factor-receptor 2 (HER2). Using the data from a case-control study in France including 975 cases and 1317 controls, we found that the odds ratios for ER+, PR+ or HER2+ breast cancers subtypes were significantly elevated, while no association with night shift work was observed for ER, PR or HER2-negative tumors. After stratification by menopausal status, the associations of night work with receptor-positive breast tumor subtypes were clearly seen in premenopausal women (odds ratios 2.04, 1.98 and 2.80, respectively) but did not appear in postmenopausal women. This study provides evidence that working at night may increase risk of ER, PR and HER2-positive subtypes of breast cancer particularly among premenopausal women.

3.Impact of MammaPrint on Clinical Decision-Making in South African Patients with Early-Stage Breast Cancer.
Pohl H1, Kotze MJ2, Grant KA2,3, van der Merwe L4,5, Pienaar FM6, Apffelstaedt JP1, Myburgh EJ1,7. Breast J. 2016 Apr 14. doi: 10.1111/tbj.12605. [Epub ahead of print]

The aim of the study was to evaluate the impact of MammaPrint on treatment decision-making in patients with breast cancer. Clinicopathologic information of all breast cancer patients referred for MammaPrint testing in South Africa was collected from 2007 until 2014. A total of 107 patients (109 tumors) with estrogen receptor/progesterone receptor positive and human epidermal growth factor receptor-2 negative tumors were selected with tumors ≥10 mm, or when 1-3 nodes were involved without extra-nodal extension. None of the clinical indicators correlated significantly with the MammaPrint risk classification, which changed the decision for adjuvant chemotherapy in 52% of patients. Of 60 patients who were clinically high risk, 62% had a low-risk MammaPrint result and of the 47 clinically low -risk patients 40% had a high-risk MammaPrint result. This study indicates that MammaPrint could reduce the need for adjuvant chemotherapy by 17% using the selection criteria stipulated.

4.Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey.
Ozmen V1, Atasoy A2, Gokmen E3, Ozdogan M4, Guler N5, Uras C6, Ok E7, Demircan O8, Isikdogan A9, Saip P10. Cureus. 2016 Mar 8;8(3):e522. doi: 10.7759/cureus.522.

INTRODUCTION: Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX(®) 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the impact of the Recurrence Score(®) (RS) on treatment decisions and physician perceptions in Turkey. We also studied correlations between RS and routine risk factors.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开